


Preparation Date: 02/2016

  
Signature

**Wayne State University  
School of Medicine CV**

**SANJAY G. REVANKAR, M.D.**

**OFFICE ADDRESS**

Division of Infectious Diseases  
Harper Hospital  
3990 John R, 5 Hudson, Room 5929  
Detroit, Michigan 48201  
(313) 745-9649  
email: srevankar@med.wayne.edu

**EDUCATION**

M.D., University of Illinois at Chicago, Chicago, IL 1987-1991

B.A., Northwestern University, Evanston, IL 1984-1987

**POSTGRADUATE TRAINING**

Pfizer Mycology Fellowship, Fungus Testing Lab,  
University of Texas Health Science Center at San Antonio, TX 1997-1999

Infectious Diseases Fellowship,  
University of Texas Health Science Center San Antonio, TX 1994-1997

Internship/Residency in Internal Medicine,  
University of Michigan Hospitals, Ann Arbor, MI 1991-1994

**FACULTY APPOINTMENTS**

Professor, Department of Internal Medicine,  
Wayne State University School of Medicine, Detroit, MI 2013-present

Associate Professor, Department of Internal Medicine,  
Wayne State University School of Medicine, Detroit, MI 2006-2013

Associate Professor, Department of Internal Medicine,  
University of Texas Southwestern Medical Center, Dallas, TX 2005-2006

Assistant Professor, Department of Internal Medicine,  
University of Texas Southwestern Medical Center, Dallas, TX 1999-2005

**HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS**

Program Director, Infectious Diseases Fellowship program, Wayne State University/Detroit Medical Center	2014-present
Chair, Infection Control Committee, Karmanos Cancer Institute	2012-present
Chair, Infection Control Committee, Harper/Hutzel Hospital	2012
Staff Physician, Detroit Medical Center, Detroit, MI	2006-present
Staff Physician, Henry Ford Hospital, Detroit MI	2006-2011
Staff Physician, Medical Service, Dallas VA Medical Center	1999-2006

**MAJOR PROFESSIONAL SOCIETIES**

International Immunocompromised Host Society	2010-present
American Society for Microbiology	1995-present
Infectious Diseases Society of America	1994-present

**MEDICAL LICENSURE**

Active: State of Michigan	1993-present
---------------------------	--------------

**BOARD CERTIFICATION**

Infectious Diseases (#155763)	1996-2026
Internal Medicine (#155763)	1994-2024

**HONORS/AWARDS**

ASM Infectious Diseases Fellow Travel Grant, 38 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy	1998
Fellow Travel Grant, 4 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections	1997
ASM Fellow Travel Grant, 35 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy	1995
Student Research Training Program Fellowship, National Cancer Institute, National Institutes of Health	1990
Alph Omega Alpha, Honor Medical Society, University of Illinois College of Medicine	1990
Dean's List, College of Arts and Sciences, Northwestern University	1984-1987

National Merit Scholarship, Northwestern University 1984-1987

### **SERVICE**

#### **Wayne State University**

Chairman, Medication Use Committee,  
Harper/ Hutzell/ Rehabilitation Institute of Michigan Hospitals 2009-2012

Member, Medication Use Committee,  
Harper/ Hutzell/ Rehabilitation Institute of Michigan Hospitals 2009-present

Education coordinator, Division of Infectious Diseases 2009-present

Wayne State University Institutional Biosafety Committee 2006-present

#### **Affiliate medical organizations**

Karmanos Hospital Practice Improvement Committee 2012-present

Karmanos Antimicrobial Subcommittee 2011-present

#### **Dallas VA Medical Center**

Veterans Integrated Service Network (VISN) 17 Research Committee 2004-2006

Dallas VA Information Management Committee 2002-2006

#### **Professional**

Member, Black Yeast Working Group,  
International Society for Human and Animal Mycology (ISHAM)  
(*Small international group focused on studying these uncommon yeast*) 2011-present

Member, Mycoses Study Group (MSG)  
(*International group based in U.S. that funds research and clinical trials involving fungal infections*) 2002-present

Member, NIH-CDC-HIVMA/IDSA Working Group:  
Guidelines for Prevention and Treatment of Opportunistic Infections  
in HIV-Infected Adults and Adolescents (Candida Subject Group) 2010-2014

Member, Department of Health and Human Services / CDC  
Panel on Guidelines for the Prevention and Treatment of Opportunistic  
Infections in HIV-Infected Adults and Adolescents  
(Mucocutaneous candidiasis working group) 2008

**Scholarly service**Service for peer-reviewed journals*Editorial board membership*

Mycopathologia

2011-present

Review of manuscripts

Acta Dermato-Venereologica

AIDS Research and Human Retroviruses

Annals of Pharmacotherapy

Antimicrobial Agents and Chemotherapy

Canadian Journal of Infectious Diseases and Medical Microbiology

Clinical Infectious Diseases

Clinical Neurology and Neurosurgery

Diagnostic Microbiology and Infectious Diseases

Environmental Monitoring and Assessment

Expert Review of Anti-infective Therapy

FEBS Letters

Hospital Practice

Infections In Medicine

Infections in Obstetrics and Gynecology

Journal of Antimicrobial Chemotherapy

Journal of Clinical Microbiology

Journal of Infection and Chemotherapy

Journal of Infectious Diseases

Medical Mycology

Mycoses

Mycopathologia

Ophthalmic Plastic and Reconstructive Surgery

Pediatric Infectious Diseases Journal

Transplant Infectious Disease

Other scholarly serviceAustrian Science Fund: Review of national grant, "Mucormycete-  
Identification and Detection of Antifungal Resistance"

2014

Wellcome Trust Global Health Trials:

"A randomized, open-label comparative study of itraconazole vs.  
amphotericin B for the treatment of penicilliosis in Vietnam"[*Clinical trial protocol review*]

2011

Texas Department of Health:

"Potential Health Effects from Mold Exposure in Buildings"

[*State training course review*]

2004

**TEACHING****Wayne State University**Physician Assistant students

Upper respiratory infections lecture (annually)	2011-present
---	--------------

Medical students

Inpatient rounding/bedside instruction (6 months/year)	2006-2012
--	-----------

Infectious Disease tutorial case discussion (monthly)	2006-present
---	--------------

I.D. case lecture (bi-monthly)	2010-2012
--------------------------------	-----------

Hepatitis lecture (bi-monthly)	2007-2012
--------------------------------	-----------

Microbiology case studies (4-6 sessions annually)	2007-present
---	--------------

Residents/fellows

Inpatient rounding/bedside instruction (6 months/year)	2006-present
--	--------------

CNS infection, Tick-borne infection, Pulmonary fungal infection lectures	2011, 2015
--	------------

Fungal respiratory infections lecture	2009
---------------------------------------	------

Clinicopathologic Conference	2008
------------------------------	------

Systemic fungal infections lecture	2008, 2015
------------------------------------	------------

Phaeohyphomycosis, Infections in burn patients lectures	2007
---	------

Clinical implications of mycotoxins and <i>Stachybotrys</i> , Medical Grand Rounds	2007
--	------

Faculty

Fungal infections in transplantation (Infections in Transplantation and HIV seminar, Henry Ford Hospital, May 2015)	2015
---	------

I.D. Update conference: Fungal infections for the Internist (September 2014)	2014
--	------

Fungal update lecture, Michigan State Medical Society Spring Scientific Meeting	2012
---	------

Stem cell transplant case discussion, combined WSU and University of Toronto transplant Infectious Diseases conference, (Toronto)	2011
---	------

**UT Southwestern Medical Center, Dallas, TX**Medical students

Inpatient rounding/bedside instruction (6 months/year)	2000-2006
--	-----------

Endemic Mycoses lecture (annual)	2004
Fungal Infections lecture (annual)	2003
Fungal Infections in AIDS lecture (annual)	2000-2005
Medical Microbiology course (Small group teaching sessions)	2002-2004
Medical Microbiology course (Mycology lab instructor)	2005
<u>Residents/fellows</u>	
Inpatient rounding/bedside instruction (6 months/year)	2000-2006
Clinicopathologic Conference (annual), Dallas VAMC	2000-2005
Medically Important Fungi lecture (annual)	2001, 2003, 2005
Zoonoses lecture	2004
Diagnosis and treatment of systemic Fungal Infections (annual)	2002, 2004
Rickettsia and Ehrlichia lecture (annual)	2000, 2004
Who's afraid of <i>Stachybotrys</i> ?, Internal Medicine Grand Rounds	2002
Tick-borne Infections lecture	2000
<u>Faculty</u>	
Antifungal therapy lecture, UT Southwestern Internal Medicine Update	2000, 2002, 2003
<b>University of Texas Health Science Center at San Antonio</b>	
<u>Medical students</u>	
Infectious Diseases Case Study Group, Discussion leader	1996, 1997, 1998
<u>Residents/fellows</u>	
Morbidity and Mortality Conference, Discussion Leader	1995, 1997
<b><u>RESEARCH MENTORING</u></b>	
Eunice Wong, Infectious Diseases fellow	2015
Dematiaceous mold review article	
Najia Huda, MD, Assistant Professor, Pulmonary/Critical Care: Improving the management of candidemia: Cytokines as a prognostic factor	Apr 2012-present

Manish Thakur, MD, Internal Medicine resident:  
 In Vitro Interaction Of Caspofungin With Immunosuppressive Agents  
 Against Zygomycetes (*Publication #1*) Jan 2010-Sep 2010

Suneetha Narreddy, MD, Infectious Diseases Fellow:  
 In vitro Interaction of Posaconazole with Calcineurin Inhibitors (CI)  
 against Zygomycetes (*Publication #3*) Feb 2007- Jan 2008

Dipti Agrawal, MD, Infectious Diseases Fellow:  
 Variables Affecting the Trailing Endpoint Phenotype in Antifungal  
 Susceptibility Testing (*Publication #5*) Jul 2000-Jun 2001

### **GRANTS, CONTRACTS AND OTHER FUNDING**

#### **Active National/International Grants and Contracts:**

MSG-06: A case registry of patients with phaeohyphomycosis  
 (International, multicenter study). Source: Merck, Astellas, Gilead through  
 the Mycoses Study Group (MSG). Jun 2011-Jun2016  
 \$443,000. Co-Principal investigator (Investigator initiated). 5% effort.

#### **Active Other Grants and Contracts:**

#### **Previously funded Grants and Contracts:**

Improving the management of candidemia: Cytokines as a prognostic factor  
 (Trans-Disciplinary Research Grant). Source: WSU Dept of Medicine  
 \$20,000. PI (Investigator initiated). 5% effort. Oct 2012-Sep 2013

In Vitro Interaction Of Caspofungin With Immunosuppressive Agents  
 Against Zygomycetes. Source: Merck.  
 \$18,000. PI (Investigator initiated). 5% effort. Dec 2008-Dec 2010

Posaconazole and calcineurin inhibitors against zygomycetes.  
 Source: Schering-Plough Research.  
 \$10,000. PI (Investigator initiated). 5% effort. Jul 2007-Jun 2008

Antifungal Susceptibility and Epidemiology of Yeast Bloodstream  
 Isolates. Source: Veterans Affairs  
 \$100,000. PI (Investigator initiated). 10% effort. 2001-2003

Trailing Endpoints in Antifungal Susceptibility Testing.  
 Source: Pfizer \$6,000. PI (Investigator initiated). 5% effort. 2000-2001

**CLINICAL TRIALS ACTIVITIES****Wayne State University**

MSG-10: “A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Estimate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral SCY-078 vs. Standard of-Care Following Initial Intravenous Micafungin Therapy in the Treatment of Invasive Candidiasis (Including Candidemia) in Hospitalized Nonneutropenic Adults” Sponsor: Scynexis. Aug 2015-present (Site PI for multi-center trial)	Aug 2015-present
“A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with <i>Clostridium difficile</i> associated diarrhea.” Sponsor: Actelion (Site PI for multi-center trial)	May 2014-present
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Sponsor: Astellas (Site PI for multi-center trial)	Apr 2012-2014
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT Study) - Part 1 Prospective Collection and Freezing of Whole Blood Specimens. Source: T2 Biosystems (Site PI for multi-center trial)	Apr 2012-2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to <i>Clostridium difficile</i> toxin A), MK-6072 (Human Monoclonal Antibody to <i>Clostridium difficile</i> toxin B), and MK-3415A (Human Monoclonal Antibodies to <i>Clostridium difficile</i> toxin A and toxin B) in Patients Receiving Antibiotic Therapy for <i>Clostridium difficile</i> Infection. Source: Merck. (Site PI for multi-center trial)	Apr 2012-2014
MSG-04 (Merck Caspofungin Protocol 067): A Pilot, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Empirical Therapy for Invasive Candidiasis in High-Risk Patients in the Critical Care Setting. Sponsor: Merck. (Site PI for multi-center trial)	Jun 2011-Jun 2012
Prospective Study of Ophthalmologic Function in Patients Receiving Linezolid for Two Months or Greater. Sponsor: Pfizer.(Site PI for multi-center trial)	Jan 2009-Jun 2012
MSG-01: A randomized, double-blind, placebo controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Sponsor: Merck. (Site PI for multi-center trial)	Oct 2007-Oct 2009



Phase IV open-label non-comparative trial of IV anidulafungin followed by oral azole therapy for the treatment of candidemia and invasive candidiasis. Sponsor: Pfizer. (Site PI for multi-center trial)

Sept 2007-Oct 2009

### **Dallas VA Medical Center**

A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Sponsor: Merck. (Site PI for multi-center trial)

Jan 2006-Apr 2006

### **PUBLICATIONS (\* indicates trainee)**

#### **Peer reviewed publications:**

#### Reports of original work

1. Jain T, Crowell C, Urdy-Cornejo V, Awali R, Cutright J, Salimnia H, Reddy Banavasi HV, Liubakka A, Lephart P, Chopra T, **Revankar SG**, Chandrasekar P, Alangaden G. Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. Biol Blood Marrow Transplant. 2016 Jan;22(1):157-63. Epub 2015 Jul 26.
2. **Revankar SG**, Moudgal V, Chandrasekar P, Sobel JD. In vitro studies of Exserohilum rostratum with antifungal drugs and methylprednisolone. Antimicrob Agents Chemother. 58(6):3564-3565, 2014.
3. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, **Revankar SG**, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 58(9):1219-1226, 2014.
4. Thakur M\*, **Revankar SG**. In vitro interaction of caspofungin and immunosuppressives against agents of mucormycosis. J Antimicrob Chemother. 66(10):2312-2314, 2011. [*Journal impact factor (JIF) 5.068, citation index (CI) 0 (# times cited); Mentored first author during residency*]
5. **Revankar SG**, Hasan MS, Revankar VS, Sobel JD. Long-term follow-up of patients with candiduria. Eur J Clin Microbiol Infect Dis 30(2):137-140, 2011. [*JIF 2.859, CI 0*]
6. Narreddy S\*, Manavathu E, Chandrasekar PH, Alangaden GJ, **Revankar SG**. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother 65(4):701-703, 2010. [*JIF 5.068, CI 6; Mentored first author during fellowship*]

7. Goetz LL, Howard M, Cipher D, **Revankar SG**. Occurrence of candiduria in a population of chronically catheterized patients with spinal cord injury. *Spinal Cord* 48(1):51-54, 2010. [JIF 1.805, CI 2]
8. Agrawal D\*, Patterson TF, Rinaldi MG, **Revankar SG**. Trailing end-point phenotype of *Candida* spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. *J Med Microbiol* 56(7):1003-1004, 2007. [JIF 2.502, CI 3; *Mentored first author during fellowship*]
9. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, Schuster M, Wingard JR, Gonzalez CE, **Revankar SG**, Corcoran G, Kryscio RJ, Hare R. Posaconazole as salvage therapy for zygomycosis. *Antimicrob Agents Chemother* 50(1):126-33, 2006. [JIF 4.841, CI 204; *Performed research, reviewed manuscript*]
10. **Revankar SG**, Fu J, Rinaldi MG, Kelly SL, Keller SM, Wickes BL. Cloning and characterization of the lanosterol 14 $\alpha$ -demethylase (ERG11) gene in *Cryptococcus neoformans*. *Biochem Biophys Res Comm* 324(2):719-728, 2004. [JIF 2.484, CI 11]
11. O'Donnell K, Sutton DA, Rinaldi MG, Magnon KC, Cox PA, **Revankar SG**, Sanche S, Geiser DM, Juba JH, van Burik JH, Padhye A, Anaissie EJ, Francesconi A, Walsh TJ, Robinson JS. Genetic diversity of human pathogenic members of the *Fusarium oxysporum* complex inferred from gene genealogies and AFLP analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin. *J Clin Microbiol* 42(11):5109-5120, 2004. [JIF 4.153, CI 70; *Performed research, reviewed manuscript*]
12. **Revankar SG**, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. *Clin Infect Dis* 38(2):206-216, 2004. [JIF 9.154, CI 95]
13. **Revankar SG**, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. *Clin Infect Dis* 34(4):467-476, 2002. [JIF 9.154, CI 140]
14. Nucci M, Akiti T, Barreiros G, Silveira F, **Revankar SG**, Wickes BL, Sutton DA, Patterson TF. Nosocomial Outbreak of *Exophiala jeanselmei* Fungemia Associated with Contamination of Hospital Water. *Clin Infect Dis* 34(11):1475-1480, 2002. [JIF 9.154, CI 24; *Performed research, reviewed manuscript*]
15. Cardona-Castro N, **Revankar SG**, Ortiz P, Cuervo C, Kirkpatrick WR, McAtee RK, Patterson TF. Proteinase Detection, DNA Typing and Antimycotic Susceptibility of *Candida* Isolates from Colombian Women with Vulvovaginal Candidiasis. *Rev Iberoam Micol* 19(2):89-94, 2002. [JIF n/a, CI n/a; *Performed research, reviewed manuscript*]
16. Nucci M, Akiti T, Barreiros G, Silveira F, **Revankar SG**, Sutton DA, Patterson TF. Nosocomial Fungemia Due to *Exophiala jeanselmei* var. *jeanselmei* and a *Rhinocladiella*

- Species: Newly Described Causes of Bloodstream Infection. *J Clin Microbiol* 39(2):514-518, 2001. [*JIF* 4.153, *CI* 32; *Performed research, reviewed manuscript*]
17. Al-Abdely HM, **Revankar SG**, Graybill JR. Disseminated *Mycobacterium simiae* infection in patients with AIDS. *J Infect* 41(2):143-147, 2000. [*JIF* 4.126, *CI* 20; *Performed research, reviewed manuscript*]
  18. Sutton DA, Sanche SE, **Revankar SG**, Fothergill AW, Rinaldi MG. In Vitro Amphotericin B Resistance in Clinical Isolates of *Aspergillus terreus*, with a Head-to-Head Comparison to Voriconazole. *J Clin Microbiol* 37(7):2343-2345, 1999. [*JIF* 4.126, *CI* 141; *Performed research, reviewed manuscript*]
  19. **Revankar SG**, Sutton DA, Sanche SE, Rao J, Zervos M, Dashti F, Rinaldi MG. *Metarrhizium anisopliae* as a cause of sinusitis in immunocompetent hosts. *J Clin Microbiol* 37(1):195-198, 1999. [*JIF* 4.126, *CI* 18]
  20. López-Ribot JL, Kirkpatrick WR, McAtee RK, **Revankar SG**, Patterson TF. Amphotericin B-metronidazole combination against *Candida* spp. *Rev Iberoam Micol* 15(3):125-130, 1998. [*JIF* n/a, *CI* n/a; *Performed research, reviewed manuscript*]
  21. Graybill JR, Montalbo E, Kirkpatrick WR, Luther MF, **Revankar SG**, Patterson TF. Fluconazole versus *Candida albicans*: a complex relationship. *Antimicrob Agents Chemo* 42(11):2938-2942, 1998. [*JIF* 4.841, *CI* 29; *Performed research, reviewed manuscript*]
  22. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Patterson TF. Interpretation of trailing endpoints in antifungal susceptibility testing using NCCLS methodology. *J Clin Microbiol* 36(1):153-156, 1998. [*JIF* 4.153, *CI* 62]
  23. Kirkpatrick WR, **Revankar SG**, McAtee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu R, Rinaldi MG, Patterson TF. Detection of *Candida dubliniensis* in oropharyngeal samples from HIV-infected patients in North America by primary CHROMagar *Candida* screening and susceptibility testing of isolates. *J Clin Microbiol* 36(10):3007-3012, 1998. [*JIF* 4.153, *CI* 130; *Performed research, reviewed manuscript*]
  24. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Hilsenbeck SG, Patterson TF. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance. *Am J Med* 105(1):7-11, 1998. [*JIF* 5.430, *CI* 36]
  25. Kirkpatrick WR, McAtee RK, **Revankar SG**, Fothergill AW, McCarthy DI, Rinaldi MG, Patterson TF. Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of *Cryptococcus neoformans*. *J Clin Microbiol* 36(5):1330-1332, 1998. [*JIF* 4.153, *CI* 11; *Performed research, reviewed manuscript*]

26. **Revankar SG**, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Redding SW, Patterson TF. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole resistant *Candida* in human immunodeficiency virus-infected patients. *Clin Infect Dis* 26(4):960-963, 1998. [*JIF* 9.154, *CI* 42]
27. Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, **Revankar SG**, Patterson TF. Cell wall proteinaceous components in isolates of *Candida albicans* and non-*albicans* species from HIV-infected patients with oropharyngeal candidiasis. *Rev Iberoam Micol* 15:125-130, 1998. [*JIF* n/a, *CI* n/a; *Performed research, reviewed manuscript*]
28. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Patterson TF. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. *J Infect Dis* 174(4):821-827, 1996. [*JIF* 6.410, *CI* 78]
29. Patterson TF, **Revankar SG**, Kirkpatrick WR, Dib OP, Fothergill AW, Redding SW, Sutton DA, Rinaldi MG. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. *J Clin Microbiol* 34(7):1794-1797, 1996. [*JIF* 4.153, *CI* 46; *Performed research, reviewed manuscript*]
30. Patterson TF, Kirkpatrick WR, **Revankar SG**, McAtee RK, Fothergill AW, McCarthy DI, Rinaldi MG. Comparative evaluation of macrodilution and chromogenic agar screening for fluconazole susceptibility of *Candida albicans*. *J Clin Microbiol* 34(12):3237-3239, 1996. [*JIF* 4.153, *CI* 20; *Performed research, reviewed manuscript*]
31. Tiballi RN, He X, Zarins LT, **Revankar SG**, Kauffman CA. Use of a colorimetric system for yeast susceptibility testing. *J Clin Microbiol* 33(4):915-917, 1995. [*JIF* 4.153, *CI* 67; *Performed research, reviewed manuscript*]
32. Walsh TJ, Whitcomb PO, **Revankar SG**, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. *Cancer* 76(11):2357-2362, 1995. [*JIF* 4.771, *CI* 56; *Performed research, reviewed manuscript*]
33. Welage LS, Carver PL, **Revankar SG**, Person C, Kauffman CA. Alterations in Gastric Acidity in Patients Infected with Human Immunodeficiency Virus. *Clin Infect Dis* 21(6):1431-1438, 1995. [*JIF* 9.154, *CI* n/a; *Performed research, reviewed manuscript*]

#### Case Reports

34. Alhusseini M\*, Miceli MH\*, Chandrasekar P, **Revankar S**. Catheter-related bloodstream infection due to *Mycobacterium neoaurum* in a patient with acute leukemia. *Leuk Lymphoma*. 55(8):1933-1934, 2014.
35. Iyer SP\*, Movva K\*, Wiebel M, Chandrasekar P, Alangaden G, Carron M, Tranchida P, **Revankar SG**. Cryptococcal meningitis presenting as sinusitis in a renal transplant recipient. *Transpl Infect Dis*. 2013 Oct;15(5):E187-90.
36. Arora NP\*, Reyes-Sacin C\*, Sadaps S\*, **Revankar SG**. Pulmonary Fungus Ball in a Patient With Sarcoidosis. *Am J Med Sci*. Dec 28,2012. [*JIF* 1.391]

37. Jain M, **Revankar SG**. A case of peritoneal histoplasmosis in a patient receiving chronic ambulatory peritoneal dialysis. *Mycoses* 55(1):99-100, 2012. [*JIF* 2.247, *CI* 0]
38. **Revankar SG**. *Cladophialophora bantiana* brain abscess in an immunocompetent patient. *Can J Infect Dis Med Microbiol* 22(4): 149-150, 2011. [*JIF* 1.538, *CI* 0]
39. Sethi S\*, Tajeja N\*, Singh J\*, Arabi H\*, Dave M\*, Badheka A\*, **Revankar S**. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma. *Am J Med Sci* 338(6):522-524, 2009. [*JIF* 1.391, *CI* n/a; *Other authors are students and residents, reviewed manuscript*]
40. Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, **Revankar SG**. Successful treatment of primary cutaneous *Aspergillus ustus* infection with surgical debridement and a combination of voriconazole and terbinafine. *Diagn Microbiol Infect Dis* 62(4):443-446, 2008. [*JIF* 2.528, *CI* 5]
41. Varelas PN, Rehman M, Pierce W, Wellwood J, Chua T\*, **Revankar S**. Vancomycin-resistant enterococcal meningitis treated with intrathecal streptomycin. *Clin Neurol Neurosurg* 110(4):376-380, 2008. [*JIF* 1.581, *CI* n/a; *Marked author was I.D. fellow*]
42. **Revankar SG**, Hasan MS, Smith JW. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. *Med Mycol* 45(2):183-185, 2007. [*JIF* 2.457, *CI* 5]
43. Lai WS, Amirkhan RH, **Revankar SG**. A case of gastrointestinal zygomycosis in a patient with gastric adenocarcinoma. *Infect Dis Clin Pract* 13:1-3, 2005. [*JIF* n/a, *CI* n/a]
44. **Revankar SG**, Gregg CR. Disseminated Cryptococcosis in an AIDS Patient Diagnosed by Examination of a Peripheral Blood Smear. *Eur J Clin Microbiol Infect Dis* 19(11):887-888, 2000. [*JIF* 2.859, *CI* n/a]
45. **Revankar SG**, Applegate AL, Markovitz DM. Delirium associated with acyclovir treatment in a patient with renal failure. *Clin Infect Dis* 21(2):435-436, 1995. [*JIF* 9.154, *CI* 19]

#### Review Articles

46. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2015. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com).
47. **Revankar SG**. Phaeohyphomycosis in transplant patients. *J Fungi*. 2016, 2(1),2. Epub Dec 22, 2015
48. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2014. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com).

49. **Revankar SG**, Sobel JD. Are Echinocandins Better Than Azoles for Invasive Candidiasis? *Current Fungal Infection Reports*. 2013;7:79-82.
50. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2013. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com).
51. **Revankar SG**. Epidemiology of black fungi. *Curr Fungal Infect Rep* 6:283-287, 2012.
52. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2011. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com). [*JIF n/a, CI n/a*]
53. **Revankar SG**, Sutton DA. Melanized fungi in human disease. *Clin Microbiol Rev* 23(4):884-928, 2010. [*JIF 16.129, CI 14; Personally reviewed >500 articles*]
54. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2010. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com). [*JIF n/a, CI n/a*]
55. **Revankar SG**. Clinical and treatment aspects of brown-black fungi. *Curr Fungal Infect Rep* 4:46–51, 2010. [*JIF n/a, CI n/a*]
56. **Revankar SG** and Sobel JD. Yeast Infections of the Lower Urinary Tract: Standards and Recommendations for Diagnosis and Treatment. *Curr Fungal Infect Rep* 4:175–178, 2010. [*JIF n/a, CI n/a*]
57. Sobel JD and **Revankar SG**. Systemic candidiasis. *BMJ Point of Care* 2009. [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com). [*JIF n/a, CI n/a*]
58. **Revankar SG**, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. *Future Microbiol* 3(1):9-17, 2008. [*JIF 3.819, CI 5*]
59. **Revankar SG**. Dematiaceous fungi. *Mycoses* 50(2):91-101, 2007. [*JIF 2.247, CI 29*]
60. **Revankar SG**. Phaeohyphomycosis. *Infect Dis Clin North Am* 20(3):609-620, 2006. [*JIF 3.029, CI 32*]
61. **Revankar SG**. Therapy of Infections caused by dematiaceous fungi. *Expert Rev Anti-Infect Ther* 3(4):601-612, 2005. [*JIF n/a, CI n/a*]
62. **Revankar SG**. Dematiaceous fungi. *Sem Resp Crit Care Med* 25(2):183-190, 2004. [*JIF 2.429, CI 13*]
63. **Revankar SG**, Clinical implications of mycotoxins and *Stachybotrys*. *Am J Med Sci* 325(5):262-274, 2003. [*JIF 1.391, CI 10*]
64. **Revankar SG**, Clark RA. Infected cardiac myxoma: case report and literature review. *Medicine* 77(5):337-344, 1998. [*JIF 4.350, CI 23*]

65. **Revankar SG**, Patterson TF. Aspergillus and Candida infections in bone marrow transplantation: Progress and controversies. *Infect Dis Clin Prac* 6:506-512, 1997. [*JIF n/a, CI 4*]
66. Al-Abdely H, **Revankar SG**, Graybill JR. Lipid formulations of amphotericin B. *Semin Resp Crit Care Med* 18(3):289-299, 1997. [*JIF 2.429, CI n/a; co-wrote manuscript*]

#### **Editorials:**

67. Sobel JD, **Revankar SG**. Echinocandins--first-choice or first-line therapy for invasive candidiasis? *N Engl J Med* 356(24):2525-2526, 2007. [*JIF 53.298, CI 21*]

#### **Letters to the Editor:**

68. Chandrasekar PH, **Revankar SG**. Cryptococcosis in a febrile renal transplant recipient. *JAMA*. 2013 Aug 21;310(7):748.
69. **Revankar SG**, Patterson J, Sutton DA, and Rinaldi MG. Central Venous Catheters as a Risk Factor for Disseminated Phaeohyphomycosis? Reply. *Clin Infect Dis* 2002;35(8): 1023-1024. [*JIF 9.154, CI 0*]
70. **Revankar SG**, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of Highly Active Anti-Retroviral Therapy (HAART) on Recurrent oropharyngeal Candidiasis in HIV-infected patients. *AIDS* 12(18):2511-2513, 1998. [*JIF 6.245, CI 24*]

#### **Books Authorships, Editorships and Chapters:**

71. **Revankar SG** and Sobel JD. Fungal infections. Merck Manual Home Edition. 2015
72. **Revankar SG** and Sobel JD. Fungi. Merck Manual Professional Edition. 2014
73. **Revankar SG**. Filamentous Fungi Other than Aspergillus and Zygomycetes in Transplant Recipients: In: Singh N, editor. *Transplant Infections*. www.antimicrobe.org. 2012.
74. **Revankar SG** and Sobel JD. Mucosal Candidiasis. In: Calderone RA and Clancy CJ, editors. *Candida and Candidiasis*, 2nd Edition, ASM Press, Washington, DC, 2012
75. **Revankar SG**. Dematiaceous fungi (Chromoblastomycosis, Mycetoma, Phaeohyphomycosis): In: Singh N, editor. *Antimicrobial Therapy and Vaccines: Vol. 1: Microbes*. www.antimicrobe.org. 2011.
76. Boros DL, **Revankar SG**. Granulomatous diseases. In: EMPIRIC (www.antimicrobe.org), Yu VL, Burdette SD. (Ed). *ESun Technologies*, Pittsburgh, PA., 2010.
77. **Revankar SG**. Current Advances in Dematiaceous Mycotic Infections. In: M.K Rai, and P.D. Bridge, editors. Applied Mycology. CAB International; 2009.

78. **Revankar SG.** Phaeohyphomycosis. In: Mandell G, Kauffman CA, editors. Atlas of Fungal Infections. Current Medicine; 2007.
79. Nath SK, **Revankar SG.** Problem-based Microbiology. Elsevier Publishers; 2006. [Textbook primarily for 2<sup>nd</sup> year medical students]
80. **Revankar SG.** Dematiaceous fungi (Chromoblastomycosis, Mycetoma, Phaeohyphomycosis): In: Singh N, editor. Antimicrobial Therapy and Vaccines: Vol. 1: Microbes. www.antimicrobe.org. 2006.
81. **Revankar SG,** Graybill JR, Patterson TF. Anti-fungal agents and anti-fungal susceptibility testing. In: Hay R, Merz W, editors. Topley and Wilson's Microbiology and Microbial Infections: Medical Mycology. 10<sup>th</sup> ed. London: Arnold Publishers, 2005.
82. **Revankar SG.** Fungal infections. In: Gregg CR, Nassar N, Keiser P, editors. Parkland Pocket Guide to HIV Care. 3<sup>rd</sup> Ed., 2004.
83. **Revankar SG,** Graybill JR. Antifungal therapy. In: Anaissie EJ, McGinnis MR, Pfaller MA, editors. Clinical Mycology. Philadelphia: Elsevier Science, 2002.
84. Graybill JR, **Revankar SG,** Patterson TF. Anti-fungal agents and anti-fungal susceptibility testing. Vol. 4, Chapter 9. In: Collier L, editor. Topley and Wilson's Microbiology and Microbial Infections: Medical Mycology 9<sup>th</sup> ed. London: Arnold Publishers, 1997.

## PRESENTATIONS

### Poster Presentations (refereed)

1. **S.G. Revankar,** J. Baddley, S. Chen, O. Cornely, M. Vehreschild, P. Pappas and MSG-06 Investigators. MSG-06: A Registry of 90 Cases of Phaeohyphomycosis. Presented at ID Week 2015, Oct 8, San Diego, CA.
2. Mayur Ramesh, Abinav Deo, Rachna Jayaprakash, Odaliz Abreu-Lanfranco, George Alangaden, Joseph Uberti, **Sanjay Revankar,** and Pranatharthi Chandrasekar. Fecal Microbiota Transplantation: A Safe and Effective Treatment for *Clostridium difficile* Infection in Stem Cell Transplantation. Presented at ID Week 2015, Oct 8, San Diego, CA.
3. Ashok Kumar, Bruce Rottmann, Sanjay **Revankar,** and Pranatharthi Chandrasekar. Innate immune response in *Candida albicans* endophthalmitis: the role of Toll-like receptor signaling. Presented at ID Week 2015, Oct 8, San Diego, CA.
4. **S.G. Revankar,** J. Baddley, S. Chen, O. Cornely, M. Vehreschild, P. Pappas and MSG-06 Investigators. MSG-06: A Registry of 50 Cases of Phaeohyphomycosis. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2014, Washington, DC.



5. **S.G. Revankar**, V. Moudgal, P. Chandrasekar, J.D. Sobel. *In vitro* studies of *Exserohilum rostratum* with antifungal drugs and methylprednisolone. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2013, Denver, CO.
6. N. Suramaethakul\*, **S. Revankar**, H. Salimnia , P.H. Chandrasekar. Changing Trends in the Epidemiology of Bacteremia during 2007-2011 in a Cancer Hospital. Presented at ID Week 2012, Oct 17-21, San Diego, CA.
7. **Revankar SG** and Thakur M\*. In vitro interaction of caspofungin with calcineurin inhibitors and sirolimus against zygomycetes. Presented at the 50<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2010, Boston, MA.
8. Narreddy S\*, Manavathu E, Alangaden G, Chandrasekar PH, **Revankar SG**. Interaction Of Posaconazole With Calcineurin Inhibitors (CI) Against Zygomycetes. Presented at the 48<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America Meeting October 2008, Washington, DC.
9. Krishnan S, Manavathu E K, Chandrasekar P H, **Revankar SG**. Successful Treatment of Primary Cutaneous *Aspergillus ustus* Infection with a Combination of Voriconazole and Terbinafine Despite Drug Resistance; Synergistic Interaction Demonstrated in vitro. Presented at the 47<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2007, Chicago, IL.
10. Manavathu E, Krishnan S, Alangaden G, **Revankar S**, Cutright J, Cha R, Chandrasekar P. Effects of Animal and Human Sera and Blood on the bioactivity, and Influence of Grapefruit Juice on Blood concentrations of Orally Administered Voriconazole in Neutropenic Mice. IN: 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, Illinois, Abstract #A-769.
11. Nareddy S, Manavathu E, Chandrasekar PH, Alangaden GJ, **Revankar SG**. Interaction of triazoles with calcineurin inhibitors against zygomycetes. Presented at the 45<sup>th</sup> Infectious Diseases Society of America Annual Meeting, October 2007, San Diego, CA.
12. **Revankar SG**, Revankar VS, Hasan MS. Long-term follow-up of hospitalized patients with candiduria. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 31, 2004, Washington, DC.
13. Hall RG, **Revankar SG**. Time to positivity of Candida blood cultures. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30, 2004, Washington, DC.

14. **Revankar SG**, Dempsey W, Tioutiounnik N. The presence of melanin in *Rhizopus microsporus* var. *rhizopodoformis*. Presented at the 103<sup>rd</sup> General Meeting of the American Society for Microbiology, May 20, 2003, Washington, DC.
15. **Revankar SG**, Dempsey W, Tioutiounnik N, Gregg CR. Candidemia and Tolerance to Fluconazole: A Case-Control Study. Presented at the 40<sup>th</sup> Infectious Diseases Society of America Annual Meeting, October 25, 2002, Chicago, IL.
16. Agrawal D, Patterson TF, Rinaldi MG, **Revankar SG**. Variables Affecting the Trailing Endpoint Phenotype in Antifungal Susceptibility Testing. Presented at the 101<sup>st</sup> General Meeting of the American Society for Microbiology, May 23, 2001, Orlando, FL
17. Keller SM, **Revankar S**, Rinaldi MG, Woodlee GL, Wickes BL. Isolation of the *Cryptococcus neoformans* ERG11 Gene. Presented at the 100<sup>th</sup> General Meeting of the American Society for Microbiology, May 2000, Los Angeles, CA.
18. **Revankar SG**, Sutton DA, Sanche SE, Rao J, Zervos M, Dashti F, Rinaldi MG. *Metarrhizium anisopliae* as a Cause of Sinusitis in Immunocompetent Hosts. Presented at the 98<sup>th</sup> General Meeting of the American Society for Microbiology, May 1998, Atlanta, GA.
19. **Revankar SG**, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of Highly Active Anti-retroviral Therapy (HAART) on Recurrent Oropharyngeal Candidiasis in HIV-infected patients: A Complex Relationship. Presented at the 5<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 1998, Chicago, IL.
20. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Rinaldi MG, Patterson TF. Correlation of predominance of fluconazole-resistant isolates and response to therapy in recurrent oropharyngeal candidiasis in HIV-infected patients. Presented at the 35<sup>th</sup> Infectious Diseases Society of America Annual Meeting, September 1997, San Francisco, CA.
21. **Revankar SG**, Kirkpatrick WR, McAtee RK, Rinaldi MG, Patterson JE, Patterson TF. Trailing endpoints in antifungal susceptibility testing: Comparison of NCCLS and agar dilution with RFLP analysis. Presented at the 97<sup>th</sup> General Meeting of the American Society for Microbiology, May 1997, Miami Beach, FL.
22. **Revankar SG**, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Redding SW, Patterson TF. Clinical Evaluation and Microbiology of Fluconazole Resistant Oropharyngeal Candidiasis. Presented at the 4<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January 1997, Washington, DC.
23. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Patterson TF. Development of Fluconazole Resistance with Continuous vs. Intermittent Therapy in Oropharyngeal Candidiasis in HIV-infected Patients. Presented

at the 34<sup>th</sup> Infectious Diseases Society of America Annual Meeting, September 1996, New Orleans, LA.

24. **Revankar SG**, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, McGough DA, Rinaldi MG, Patterson TF. Prevalence of Fluconazole resistance in oropharyngeal candidiasis in HIV-Infected patients. Presented at the 3<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, January 1996, Washington, DC.
25. **Revankar SG**, Kirkpatrick WR, McAtee RL, Dib OP, Fothergill AW, Redding SW, Redding SW, McGough DA, Rinaldi MG, Patterson TF. Detection of fluconazole resistant yeasts with chromogenic agar. Presented at the 35<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1995, San Francisco, CA.
26. **Revankar SG**, Kirkpatrick WR, Fothergill AW, Patterson TF. Agar dilution screening for fluconazole resistant yeasts. Presented at the 95<sup>th</sup> General Meeting of the American Society for Microbiology, May 1995, Washington, DC.

#### **Invited Lectures/Presentations**

1. Aspergillosis. Medical Grand Rounds, St. Joseph/Mercy Hospital, Ann Arbor, MI. April 2014.
2. Black Mold Infection Management: What Do We Do Right and/or Wrong? Presented at the Mycological Conundra Symposium, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2013, Denver, CO.
3. “Cerebral and disseminated infections”. Symposium on clinical aspects of black yeast infections. Meeting of the ISHAM working groups on Black Yeasts and Chromoblastomycosis. Curitiba, Brazil, 1-4 December, 2011.
4. “The Changing Spectrum of Fungal Respiratory Disease” – 25<sup>th</sup> Annual Clinical Update of Pulmonary Disease (Deborah Heart and Lung Center), Atlantic City, NJ, Nov 2008
5. “Epidemiology and Management of Invasive Candidiasis and Aspergillosis” – 1st China Interscience Conference on Antimicrobial Agents and Chemotherapy, Beijing, China, Nov 2008
6. “Clinical aspects of infection due to melanized fungi” – 108<sup>th</sup> Annual Meeting of the American Society for Microbiology, Boston, MA, May 2008
7. “Dematiaceous fungi” – 18<sup>th</sup> Focus on Fungal Infections Meeting, San Antonio, TX, Apr 2008
8. “Antifungal therapy” – South Dakota School of Medicine, Medicine grand Rounds, June 2007

9. “Dematiaceous fungi” – 44<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Nov 2004
10. “Update on Candidiasis” – Medicine Grand Rounds: Annual McBee lectureship, Baylor Medical Center, Dallas, Jun 2004
11. “Invasive Phaeohyphomycosis: The Emerging Menace of the ‘Black’ Fungi” – 14<sup>th</sup> Focus on Fungal Infections Meeting, New Orleans, March 2004
12. “Phaeohyphomycosis” – 15<sup>th</sup> Congress of the International Society for Human and Animal Mycology, San Antonio, May 2003
13. “Who’s Afraid of *Stachybotrys*?” – Association for Professionals in Infection Control and Epidemiology, Arlington, Oct 2002
14. Symposia “Mycoses of Increasing Significance” – Co-chairperson, 15<sup>th</sup> Congress of the International Society for Human and Animal Mycology, San Antonio, May 2003